The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Abstract
Background: Rapamycin is a highly specific inhibitor of mTOR, a serine/threonine kinase that controls cap‐dependent translation. Here we report the activity of rapamycin against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures: Rapamycin was tested against the in vitro panel at concentrations from 0.01 to 100 nM and was tested against the in vivo tumor panels by i.p. administration daily × 5 for 6 consecutive weeks at a dose of 5 mg/kg. Results: Rapamycin variably inhibited growth of the cell lines in the PPTP in vitro panel, with maximal inhibition values ranging from 19% to 85% (median 49%) and a median EC 50 of 0.7 nM. Ten of 23 cell lines achieved at least 50% growth inhibition. Against the in vivo panels, rapamycin induced significant differences in EFS distribution in 27 of 36 solid tumor xenografts and in 5 of 8 ALL xenografts. Using the time to event activity measure, rapamycin had intermediate or high activity against 14 of 31 evaluable solid tumor xenografts and 5 of 8 ALL xenografts. Objective responses were observed in several panels, including: rhabdoid tumor (1PR), rhabdomyosarcoma (2PR), and osteosarcoma (1 maintained CR). Two T‐cell ALL xenografts had objective responses (1PR, 1 maintained CR). Conclusions: Rapamycin demonstrated broad antitumor activity against the PPTP's in vivo tumor panels, with particularly noteworthy activity for selected sarcoma and ALL xenografts. Future work will evaluate the molecular characteristics of responding models and the activity of combinations of rapamycin with other anticancer agents. Pediatr Blood Cancer 2008;50:799–805. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Cited by
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., Seif, A. E., Barrett, D. M., Chen, I.-M., Collins, J. R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415448 · Cited by 289
Mody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30355-8 · Cited by 277
Self-citation
Metadata
- Authors
- Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., & Smith, M. A.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2007-07-16
- Volume
- 50
- Issue
- 4
- Pages
- 799-805
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2003537331
- Cited by
- 158
- References
- 1
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. https://app.cochat.ai/papers/10.1002/pbc.21296
- The paper
- Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., & Smith, M. A. (2008). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.21296
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.